Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer
Abstract Introduction It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume systemic anti-neoplastic treatment in patients with cancer. We assessed the risk of admissions or postponed treatment cycle in vaccinated patients with breas...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-10-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-023-00247-2 |
| _version_ | 1797453537285767168 |
|---|---|
| author | Naama Halpern Ben Boursi Einat Shacham-Shmueli Einav Nili Gal-Yam Ofer Margalit Talia Golan Tamar Beller Gal Strauss Dafna Yahav Eyal Leshem |
| author_facet | Naama Halpern Ben Boursi Einat Shacham-Shmueli Einav Nili Gal-Yam Ofer Margalit Talia Golan Tamar Beller Gal Strauss Dafna Yahav Eyal Leshem |
| author_sort | Naama Halpern |
| collection | DOAJ |
| description | Abstract Introduction It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume systemic anti-neoplastic treatment in patients with cancer. We assessed the risk of admissions or postponed treatment cycle in vaccinated patients with breast cancer receiving early systemic anti-neoplastic treatment following SARS-CoV-2 infection. Methods This was a retrospective cohort study conducted during Omicron SARS-CoV-2 outbreak in Israel, January–July 2022. SARS-CoV-2 cohort included 30 vaccinated patients with breast cancer with SARS-CoV-2 infection 7–14 days prior to systemic treatment. All patients had resolved symptoms and a negative antigen detection test on the day of treatment. The pre-coronavirus disease 2019 (COVID-19) pandemic cohort consisted of 49 matched patients with breast cancer treated with systemic anti-neoplastic agents during 2019. Results In 30 vaccinated patients with breast cancer who received systemic anti-neoplastic treatment 7–14 days following SARS-CoV-2 infection, compared with 49 matched patients treated in 2019, the rates of emergency department (ED) visits (13% versus 6%, respectively), hospitalizations (3% versus 4%), next cycle of treatment given per protocol (90% versus 88%), and death (0% versus 0%) were similar. Conclusion In a cohort of vaccinated patients with breast cancer who received systemic anti-neoplastic treatment 7–14 days after SARS-CoV-2 infection, we did not observe substantially higher rates of ED visits, hospitalizations, or deaths compared with a similar cohort of pre-COVID-19 patients with breast cancer. Most patients received the next planned cycle on time. Early resumption of systemic anti-neoplastic treatment following SARS-CoV-2 infection in vaccinated patients with breast cancer with a negative antigen test at the day of treatment appeared to be safe. Additional data on larger cohorts and other malignancies are needed to support clinical guidelines. |
| first_indexed | 2024-03-09T15:24:18Z |
| format | Article |
| id | doaj.art-569bf89acf3341d2b5bc2b309451ade2 |
| institution | Directory Open Access Journal |
| issn | 2366-1070 2366-1089 |
| language | English |
| last_indexed | 2024-03-09T15:24:18Z |
| publishDate | 2023-10-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj.art-569bf89acf3341d2b5bc2b309451ade22023-11-26T12:36:39ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892023-10-0111451351910.1007/s40487-023-00247-2Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast CancerNaama Halpern0Ben Boursi1Einat Shacham-Shmueli2Einav Nili Gal-Yam3Ofer Margalit4Talia Golan5Tamar Beller6Gal Strauss7Dafna Yahav8Eyal Leshem9Division of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterDivision of Oncology, Sheba Medical CenterInfectious Diseases Unit, Sheba Medical CenterInfectious Diseases Unit, Sheba Medical CenterAbstract Introduction It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume systemic anti-neoplastic treatment in patients with cancer. We assessed the risk of admissions or postponed treatment cycle in vaccinated patients with breast cancer receiving early systemic anti-neoplastic treatment following SARS-CoV-2 infection. Methods This was a retrospective cohort study conducted during Omicron SARS-CoV-2 outbreak in Israel, January–July 2022. SARS-CoV-2 cohort included 30 vaccinated patients with breast cancer with SARS-CoV-2 infection 7–14 days prior to systemic treatment. All patients had resolved symptoms and a negative antigen detection test on the day of treatment. The pre-coronavirus disease 2019 (COVID-19) pandemic cohort consisted of 49 matched patients with breast cancer treated with systemic anti-neoplastic agents during 2019. Results In 30 vaccinated patients with breast cancer who received systemic anti-neoplastic treatment 7–14 days following SARS-CoV-2 infection, compared with 49 matched patients treated in 2019, the rates of emergency department (ED) visits (13% versus 6%, respectively), hospitalizations (3% versus 4%), next cycle of treatment given per protocol (90% versus 88%), and death (0% versus 0%) were similar. Conclusion In a cohort of vaccinated patients with breast cancer who received systemic anti-neoplastic treatment 7–14 days after SARS-CoV-2 infection, we did not observe substantially higher rates of ED visits, hospitalizations, or deaths compared with a similar cohort of pre-COVID-19 patients with breast cancer. Most patients received the next planned cycle on time. Early resumption of systemic anti-neoplastic treatment following SARS-CoV-2 infection in vaccinated patients with breast cancer with a negative antigen test at the day of treatment appeared to be safe. Additional data on larger cohorts and other malignancies are needed to support clinical guidelines.https://doi.org/10.1007/s40487-023-00247-2COVID-19SARS-CoV-2Breast cancerChemotherapyOncology |
| spellingShingle | Naama Halpern Ben Boursi Einat Shacham-Shmueli Einav Nili Gal-Yam Ofer Margalit Talia Golan Tamar Beller Gal Strauss Dafna Yahav Eyal Leshem Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer Oncology and Therapy COVID-19 SARS-CoV-2 Breast cancer Chemotherapy Oncology |
| title | Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer |
| title_full | Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer |
| title_fullStr | Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer |
| title_full_unstemmed | Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer |
| title_short | Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer |
| title_sort | early systemic anti neoplastic treatment post sars cov 2 infection in patients with breast cancer |
| topic | COVID-19 SARS-CoV-2 Breast cancer Chemotherapy Oncology |
| url | https://doi.org/10.1007/s40487-023-00247-2 |
| work_keys_str_mv | AT naamahalpern earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT benboursi earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT einatshachamshmueli earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT einavniligalyam earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT ofermargalit earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT taliagolan earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT tamarbeller earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT galstrauss earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT dafnayahav earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer AT eyalleshem earlysystemicantineoplastictreatmentpostsarscov2infectioninpatientswithbreastcancer |